NYSEAMERICAN:MTNB Matinas BioPharma (MTNB) Stock Price, News & Analysis → Urgent Nvidia Warning (From Altimetry) (Ad) Free MTNB Stock Alerts $0.17 -0.01 (-5.41%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$0.17▼$0.1950-Day Range N/A52-Week Range$0.11▼$0.89Volume1.45 million shsAverage Volume913,478 shsMarket Capitalization$38.04 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort Interest Get Matinas BioPharma alerts: Email Address Matinas BioPharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,615.3% Upside$3.00 Price TargetShort InterestHealthy1.47% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.50Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.51 out of 5 stars 3.5 Analyst's Opinion Consensus RatingMatinas BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageMatinas BioPharma has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.47% of the outstanding shares of Matinas BioPharma have been sold short.Short Interest Ratio / Days to CoverMatinas BioPharma has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Matinas BioPharma has recently decreased by 2.45%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldMatinas BioPharma does not currently pay a dividend.Dividend GrowthMatinas BioPharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MTNB. Previous Next 1.9 News and Social Media Coverage News SentimentMatinas BioPharma has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Matinas BioPharma this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for MTNB on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Matinas BioPharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.60% of the stock of Matinas BioPharma is held by insiders.Percentage Held by InstitutionsOnly 11.77% of the stock of Matinas BioPharma is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Matinas BioPharma is -1.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Matinas BioPharma is -1.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMatinas BioPharma has a P/B Ratio of 1.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsFW: 234x GainThis coin is an essential building block for an ongoing financial revolution of massive dimensions. As a big part of this revolution, the big banks of the world must connect to the blockchain.Click here. About Matinas BioPharma Stock (NYSEAMERICAN:MTNB)Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It also offers MAT2501, an orally administered formulation of amikacin to treat chronic and acute bacterial infections, as well as non-tuberculosis mycobacterium. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases for the development of oral formulations of Gilead's remdesivir; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.Read More MTNB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MTNB Stock News HeadlinesMay 2, 2024 | globenewswire.comMatinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024April 30, 2024 | msn.comOral fungal infection treatment shows promise in preclinical trialsMay 4, 2024 | Colonial Metals (Ad)The asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.April 30, 2024 | finance.yahoo.comIn Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and ChemotherapyApril 3, 2024 | msn.comMatinas Declines on Public OfferingApril 3, 2024 | globenewswire.comMatinas BioPharma Prices $10 Million Registered Direct OfferingApril 1, 2024 | finance.yahoo.comMatinas BioPharma Holdings, Inc. (AMEX:MTNB) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | finanznachrichten.deMatinas BioPharma Holdings, Inc.: Matinas BioPharma Reports 2023 Financial Results and Provides a Business UpdateMay 4, 2024 | Colonial Metals (Ad)The asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.March 28, 2024 | finance.yahoo.comQ4 2023 Matinas BioPharma Holdings Inc Earnings CallMarch 27, 2024 | investorplace.comMTNB Stock Earnings: Matinas BioPharma Hldgs Reported Results for Q4 2023March 27, 2024 | globenewswire.comMatinas BioPharma Reports 2023 Financial Results and Provides a Business UpdateMarch 25, 2024 | finanznachrichten.deMatinas BioPharma Holdings, Inc.: Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel FormulationMarch 25, 2024 | globenewswire.comMatinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel FormulationMarch 22, 2024 | finance.yahoo.comWhy Is Fungal Infections-Focused Matinas BioPharma Stock Trading Higher On Friday?March 22, 2024 | finance.yahoo.comThree Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical ResponseMarch 22, 2024 | globenewswire.comThree Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical ResponseMarch 22, 2024 | globenewswire.comMatinas BioPharma Regains Compliance with NYSE American Continued Listing StandardsMarch 3, 2024 | uk.finance.yahoo.comMatinas BioPharma Holdings, Inc. (MTNB)February 28, 2024 | wsj.comMatinas BioPharma Holdings Inc.February 26, 2024 | finance.yahoo.comMatinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical ResolutionFebruary 23, 2024 | benzinga.comMatinas BioPharma Hldgs Stock (AMEX:MTNB) Dividends: History, Yield and DatesFebruary 20, 2024 | finance.yahoo.comMatinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive AspergillosisFebruary 20, 2024 | globenewswire.comMatinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive AspergillosisFebruary 4, 2024 | seekingalpha.comAVBP ArriVent BioPharma, Inc.January 21, 2024 | morningstar.comMatinas BioPharma Holdings Inc MTNBJanuary 3, 2024 | finance.yahoo.comMatinas BioPharma to Present at Biotech Showcase 2024See More Headlines Receive MTNB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Matinas BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/27/2024Today5/04/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNYSEAMERICAN:MTNB CUSIPN/A CIKN/A Webwww.matinasbiopharma.com Phone(908) 484-8805FaxN/AEmployees32Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$3.00 Low Stock Price Target$3.00 Potential Upside/Downside+1,615.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,940,000.00 Net MarginsN/A Pretax Margin-2,093.25% Return on Equity-89.20% Return on Assets-72.15% Debt Debt-to-Equity RatioN/A Current Ratio5.93 Quick Ratio5.93 Sales & Book Value Annual Sales$1.10 million Price / Sales34.58 Cash FlowN/A Price / Cash FlowN/A Book Value$0.09 per share Price / Book1.94Miscellaneous Outstanding Shares217,480,000Free Float196,605,000Market Cap$38.04 million OptionableNot Optionable Beta1.62 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Jerome D. Jabbour J.D. (Age 50)Co-Founder, CEO, President & Director Comp: $842.38kDr. Theresa Matkovits Ph.D. (Age 57)Chief Development Officer Comp: $570.08kDr. James J. Ferguson FACC (Age 70)M.D., Chief Medical Officer Comp: $621kMr. Keith A. Kucinski CPA (Age 54)M.B.A., Chief Financial Officer Comp: $249.05kDr. Hui Liu M.B.A. (Age 56)Ph.D., Chief Technology Officer Mr. Frank CalamusaExecutive Director and Head of Manufacturing & Supply ChainMr. Thomas J. Hoover M.B.A. (Age 54)Chief Business Officer More ExecutivesKey CompetitorsLexaria BioscienceNASDAQ:LEXXCara TherapeuticsNASDAQ:CARAOcuphire PharmaNASDAQ:OCUPUnicycive TherapeuticsNASDAQ:UNCYImmuneeringNASDAQ:IMRXView All CompetitorsInstitutional OwnershipPrivate Advisor Group LLCBought 80,000 shares on 2/6/2024Ownership: 0.155%Sargent Investment Group LLCSold 105,000 shares on 2/5/2024Ownership: 1.757%View All Institutional Transactions MTNB Stock Analysis - Frequently Asked Questions Should I buy or sell Matinas BioPharma stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Matinas BioPharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" MTNB shares. View MTNB analyst ratings or view top-rated stocks. What is Matinas BioPharma's stock price target for 2024? 1 Wall Street analysts have issued 1-year price objectives for Matinas BioPharma's stock. Their MTNB share price targets range from $3.00 to $3.00. On average, they predict the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 1,615.3% from the stock's current price. View analysts price targets for MTNB or view top-rated stocks among Wall Street analysts. How have MTNB shares performed in 2024? Matinas BioPharma's stock was trading at $0.2801 on January 1st, 2024. Since then, MTNB shares have decreased by 37.6% and is now trading at $0.1749. View the best growth stocks for 2024 here. Are investors shorting Matinas BioPharma? Matinas BioPharma saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,270,000 shares, an increase of 147.7% from the March 15th total of 1,320,000 shares. Based on an average daily trading volume, of 1,520,000 shares, the days-to-cover ratio is presently 2.2 days. View Matinas BioPharma's Short Interest. When is Matinas BioPharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our MTNB earnings forecast. How were Matinas BioPharma's earnings last quarter? Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) announced its quarterly earnings results on Wednesday, March, 27th. The company reported ($0.03) EPS for the quarter. What other stocks do shareholders of Matinas BioPharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Matinas BioPharma investors own include KushCo (KSHB), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), Organigram (OGI), Novan (NOVN), Zosano Pharma (ZSAN) and Aeterna Zentaris (AEZS). How do I buy shares of Matinas BioPharma? Shares of MTNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:MTNB) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchFW: 234x GainWeiss RatingsCould Your Accounts Be Frozen?Allegiance GoldThe Gold Grab of the CenturyColonial MetalsStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Matinas BioPharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.